louisiana glp-1 stomach paralysis law firm gastric stasis office in Ozempic GLP-1 Lawsuit [2026]: Gastroparesis (Stomach Paralysis), Ileus & NAION Vision Loss Injury Cases kentucky glp-1 gastric intestinal obstruction

Protocol 2: significant weight loss (20-25% body weight) Goal: Substantial weight reduction for health improvement Tirzepatide approach: Full escalation to 10-15 mg Expect to reach target dose by week 17-21 Weight loss at 15 mg: approximately 22.5% at 72 weeks Plateau typically occurs around weeks 60-72 Retatrutide approach: Full escalation to 8-12 mg Expect to reach target dose by week 13-17 Weight loss at 12 mg: 24.2% at 48 weeks, 28.7% at 68 weeks No plateau observed in trial data at 48 or 68 weeks For significant weight loss goals, retatrutide reaches 20%+ body weight reduction faster and ultimately achieves a higher ceiling

They don't have your labs, your medication history, or a relationship with you over time

Researchers study it for two main goals: helping the body shrink fat cells and raising NAD+ levels inside cells without cutting appetite

10.1056/NEJMoa1307684

A Phase 2 substudy found that retatrutide produced up to 26.1% reduction in total body fat mass while limiting lean mass loss to 6.5kg

By Ron Walker TLDR: GLP-1 drugs like Ozempic don't cause photosensitivity, but dehydration and heat intolerance make sun exposure riskier GI side effects (nausea in up to 44% of patients) plus suppressed thirst cues accelerate fluid loss outdoors Sunscreen reapplication every 2 hours is impractical when nauseous and dehydrated A UPF 50+ umbrella provides continuous physical UV protection without reapplication Patients on combo medications (metformin, HCTZ) face compounded photosensitivity risk One in eight American adults now takes a GLP-1 medication like Ozempic, Wegovy, or Zepbound, according to the KFF Health Tracking Poll